ArticleJournal of neuro-oncology2025
Decoding meningioma prognosis with multi-omics: macrophage diversity, immune-CNV interplay, and novel SPP1-targeted strategies.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Leveraging single-cell and spatial omics for brain tumour insights to improve therapeutic strategies.Molecular brain · 2026Review
- SPP1Cell death & disease · 2026Article
- Long-term neurocognitive sequelae in pediatric medulloblastoma survivors treated according to the HIT protocol.Journal of neuro-oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMeningiomas exhibit significant tumor heterogeneity leading to diverse prognosis of patients. While DNA methylation (DNAme)-based classification has shown good performance in subtyping of meningiomas, single-cell transcriptomics offer an opportunity to further explore cell population activity. Understanding the functional states of macrophage populations is especially critical in meningiomas, given their established roles in tumor progression and therapeutic response.
methodsWe performed integrated multi-omics clustering of DNAme and bulk RNA-seq data from 302 paired meningioma samples. This identified molecular types characterized by distinct survival, copy number variation (CNV), immune infiltration, and pathway enrichment profiles. Single-cell RNA-seq (scRNA-seq) validated CNV findings and enabled deconvolution of type-specific macrophage populations using SCISSOR, while scRank assessed candidate genes to identify therapeutic targets.
resultsWe identified five meningioma molecular types (CS1-CS5) with distinct recurrence risks, survival, CNV landscapes, and immune microenvironments: Proliferative (CS1), Metabolic (CS2), Mixed (CS3), Immune-Enriched (CS4), and NF2-Wild-Type (CS5). CS4 was featured by high macrophage infiltration, while CS5 showed immune-desert characteristics. Type-specific CNV profiles showed chromosome 22 deletions relating to immune infiltration, and SPP1-centered gene networks highlighted its regulatory role in macrophage plasticity. Particularly, SPP1 upregulation associated with poor prognosis in CS1 and downregulation likely contributed to better outcomes in CS4. Drug sensitivity analyses identified the potential of targeting SPP1 for macrophage reprogramming in future type-directed therapies.
conclusionOur meningioma prognostic stratification characterized macrophage functional heterogeneity and CNV-driven immune microenvironment disparities. We found SPP1 as a critical regulator for macrophage function and offering a promising candidate for future treatment to target in an aggressive molecular type.
Indexed as
Identifiers
40522564What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.